Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEGACY: Less Bleeding by Omitting Aspirin in NSTE-ACS Patients
2023-504360-42-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised trial of aspirin in non–ST-segment elevation acute coronary syndrome (NSTE-ACS), unstable angina and Non-ST-segment elevation myocardial infarction (NSTEMI) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Major or minor bleeding (BARC type 2, 3 or 5) at 12 months and Composite of all-cause mortality, myocardial infarction, and stroke at 12 months. Planned start Apr 2023; status: authorised.
02
Drugs
aspirin
03
Conditions
non–ST-segment elevation acute coronary syndrome (NSTE-ACS)unstable anginaNon-ST-segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on 2023-504360-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504360-42-00.